Bridging Anticoagulation | Circulation - AHA/ASA Journals
网页2012年3月27日 · Bridging anticoagulation refers to giving a short-acting blood thinner, usually low-molecular-weight heparin given by subcutaneous injection for 10 to 12 days around the time of the surgery/procedure, when warfarin is interrupted and its anticoagulant effect is outside a therapeutic range.
Perioperative management of patients receiving anticoagulants
网页2024年2月8日 · BRIDGING ANTICOAGULATION. Limited indications for bridging; Evidence for avoiding bridging in most individuals with atrial fibrillation; Evidence for avoiding bridging in individuals with VTE and other populations; Heparin product and dose; Timing of bridging - Preoperative timing of bridging - Postoperative timing of bridging
网页Chronic oral anticoagulation frequently requires interruption for various reasons and durations. Whether or not to bridge with heparin or other anticoagulants is a common clinical dilemma. The evidence to inform decision making is limited, making current guidelines equivocal and imprecise.
Perioperative Management of Antithrombotic Therapy - CHEST
网页2022年8月11日 · We define “heparin bridging” as the administration of a short-acting anticoagulant, typically a low-molecular-weight heparin (LMWH) or, less often, unfractionated heparin (UFH), for an 8- to 10-day perioperative period during interruption of a VKA when the international normalized ratio (INR) is below the therapeutic range. 14 …
网页Bridging anticoagulation refers to giv-ing a short-acting blood thinner, usu-ally low-molecular-weight heparin given by subcutaneous injection for 10 to 12 days around the time of the surgery/procedure, when warfarin is interrupted and its anticoagulant effect is outside a therapeutic range.
网页DEFINITIONS: Bridging: The use of a(n) subcutaneous or intravenous anticoagulant for a period of time during interruption of warfarin therapy and/or when the INR is not within a therapeutic range.
Periprocedural Bridging Management of Anticoagulation
网页2012年7月24日 · Bridging therapy is a recent term used to describe the application of a parenteral, short-acting anticoagulant during the interruption of warfarin. In this Clinician Update, we outline a systematic approach to defining the appropriate periprocedural strategy for anticoagulation management.
Perioperative Anticoagulation Management - StatPearls - NCBI Bookshelf
网页2023年1月23日 · Heparin can be administered as a therapeutic dose for patients with high thromboembolic risk (enoxaparin 1 mg/kg twice daily or dalteparin 100 units/kg twice daily) or as the prophylactic dose for patients undergoing bridge therapy (enoxaparin 40 mg once daily or dalteparin 5,000 units once daily).
Bridging Anticoagulation: - Journal of the American College of …
网页In the BRIDGE trial—a randomized, double-blinded, placebo-controlled noninferiority study—1,884 atrial fibrillation patients (valvular and nonvalvular) who were undergoing a procedure with planned warfarin interruption were randomized to anticoagulation bridging with the low molecular-weight heparin, dalteparin, or placebo . The reasons for ...
Executive Summary - CHEST
网页2022年8月11日 · “Heparin bridging” is defined as the pre- and/or post-operative administration of a therapeutic-dose regimen of low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH), focusing on LMWH bridging, which is the most widely studied regimen and has the greatest potential for benefit (reduced thromboembolism) and …